Please assess the completion status of the following clinical trial:

Trial Title: Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed relapsed/ refractory DLBCL~* Must have previously received first line treatment regimen~* Must be ineligible for high dose therapy/ stem cell transplantation~* Measurable disease sites on computed tomography (CT) scan (\>1.5 cm in longest dimension)~* prothrombin time/international normalized ratio (PT/INR) \< 1.5 x upper limit of normal (ULN) and partial thromboplastin time (PTT; activated partial thromboplastin time \[aPTT\]) \<1.5 x ULN~* Men and women ≥18 years of age~* Eastern Cooperative Oncology Group (ECOG) \< 2~* Adequate hepatic and renal function~* Adequate hematologic function~Exclusion Criteria:~* Medically apparent central nervous system lymphoma or leptomeningeal disease~* History of allogeneic stem-cell (or other organ) transplantation~* Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2 weeks~* Radio- or toxin-immunoconjugates within 10 weeks~* Concurrent enrollment in another therapeutic investigational study or have previously taken ibrutinib and/or lenalidomide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) (Type: EXPERIMENTAL): Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.
- Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) (Type: EXPERIMENTAL): De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
- Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) (Type: EXPERIMENTAL): Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
- Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) (Type: EXPERIMENTAL): Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
- Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) (Type: EXPERIMENTAL): Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
- Phase 2: Enrolled at Lenalidomide Dose 20 mg (Type: EXPERIMENTAL): Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
- Phase 2: Enrolled at Lenalidomide Dose 25 mg (Type: EXPERIMENTAL): Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete